PMC:7228307 / 488-878 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"21","span":{"begin":95,"end":99},"obj":"Gene"},{"id":"26","span":{"begin":192,"end":198},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:2213"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":199,"end":204},"obj":"Body_part"},{"id":"T6","span":{"begin":214,"end":222},"obj":"Body_part"},{"id":"T7","span":{"begin":357,"end":366},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":192,"end":198},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":95,"end":97},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T10","span":{"begin":199,"end":204},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":109,"end":117},"obj":"Chemical"},{"id":"T5","span":{"begin":334,"end":348},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_33839"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T5","span":{"begin":199,"end":204},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T1","span":{"begin":334,"end":348},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_33839"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"21","span":{"begin":95,"end":99},"obj":"Gene"},{"id":"26","span":{"begin":192,"end":198},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"pubann:denotes","subj":"21","obj":"Gene:2213"},{"id":"A26","pred":"pubann:denotes","subj":"26","obj":"MESH:D009369"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T8","span":{"begin":146,"end":380},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T5","span":{"begin":199,"end":204},"obj":"Body_part"},{"id":"T6","span":{"begin":214,"end":222},"obj":"Body_part"},{"id":"T7","span":{"begin":357,"end":366},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T1","span":{"begin":244,"end":256},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T1","span":{"begin":192,"end":198},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T1","span":{"begin":192,"end":198},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T1","span":{"begin":244,"end":256},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":244,"end":256},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-sentences","denotations":[{"id":"T8","span":{"begin":146,"end":380},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":192,"end":198},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"ibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. The use o"}